A West Australian plant used by Aboriginal communities for generations was found to contain compounds active against HIV. A US government agency filed a patent on it. The community that had known about it for millennia received nothing — and had no legal standing to object. This lesson is about who owns traditional knowledge, and why the answer matters for medicine.
Use the PDF for classwork, homework or revision. It includes key ideas, activities, questions, an extend task and success-criteria proof.
A pharmaceutical company discovers that a plant used by an Indigenous community has potent medicinal properties. They isolate the active compound, develop it into a drug, and file a patent. The drug sells for hundreds of millions of dollars per year.
Before reading: who do you think should benefit from this drug's commercial success? The company that developed it? The community whose knowledge directed researchers to the plant? The country where the plant grows? And what obligations, if any, does the company have?
Come back to this at the end of the lesson.
Wrong: Natural selection means organisms change because they want or need to.
Right: Natural selection acts on random genetic variations; organisms do not consciously adapt.
Core Content
Remember to connect the concepts in this lesson to the broader evolutionary framework. Each mechanism builds on what you have learned previously.
Bush medicine refers to the use of native Australian plants, animals, and minerals in traditional healing practices by Aboriginal and Torres Strait Islander peoples. This knowledge represents tens of thousands of years of empirical observation, trial, and refinement — a pharmacopoeia developed through direct experience of the Australian environment and its biological resources.
Bush medicine is not a relic of the past. It is actively used across Australia — particularly in remote and regional communities where access to Western medicine may be limited, but also by choice in communities where traditional healing practices are maintained as part of cultural identity and wellbeing. Knowledge of bush medicine is held by specific knowledge-holders within communities, transmitted through oral tradition, and often inseparable from spiritual and cultural frameworks.
Many bush medicine plants have had their traditional applications scientifically validated — raising significant questions about who owns this knowledge
When a pharmaceutical company, research institution, or government agency uses traditional biological knowledge to develop a commercial product — without the consent of the knowledge-holding community and without sharing benefits — this is called biopiracy. The term captures both the biological and the legal dimensions: the biological resource (the plant) and the traditional knowledge (its application) are appropriated without authorisation.
Bioprospecting and biopiracy use the same biological knowledge — the difference is consent, process, and benefit sharing
Standard patent law protects inventions that are novel, useful, and non-obvious. Traditional knowledge — including knowledge of medicinal plants — often fails on the "novelty" test from the perspective of the knowledge-holding community (it is not new to them), but it may appear novel to a patent examiner who is unaware of its traditional use. This creates a legal gap: a company can take knowledge that has existed in a community for generations, frame it as a "new discovery," and obtain patent protection — legally excluding the original knowledge-holders from commercialising the resource.
This is compounded by the fact that oral traditional knowledge is typically not documented in the forms that patent offices recognise as "prior art" — the existing knowledge base that prevents a patent from being granted on something already known. If traditional knowledge is not in a patent database, a scientific journal, or a book, a patent examiner may not find it.
The Nagoya Protocol on Access and Benefit-Sharing is an international agreement under the Convention on Biological Diversity, adopted in 2010 and entering into force in 2014. It establishes a framework requiring that:
Australia ratified the Nagoya Protocol in 2022. Implementation requires domestic legislation that gives effect to the access and benefit-sharing requirements — still developing at state and federal levels.
In the early 1990s, the US National Cancer Institute (NCI) collected samples of a Western Australian shrub known as smoke bush (Conospermum spp.) as part of a broad bioprospecting program. Laboratory screening found that compounds from the plant — later named conospermines — had significant activity against HIV in cell culture.
You will evaluate this case in Activity 01 and Short Answer Q3.
Misconception: If a company patents a natural compound it is just protecting its investment in research — this is not theft.
Patents protect novel inventions. When a compound is already known to a community — even if undocumented in Western databases — the "discovery" that enables the patent was guided by traditional knowledge. The investment in identifying the compound was reduced by the traditional knowledge that pointed researchers toward it. Without consent or benefit-sharing, the original knowledge-holders contribute to the commercial outcome without receiving any part of it. This is what the Nagoya Protocol is designed to address — ensuring the process of commercialisation is fair, not preventing research.
Misconception: Scientific validation is required before Indigenous plant knowledge can be considered legitimate medical knowledge.
This reflects a hierarchical view of knowledge that is both ethically problematic and scientifically inaccurate. Traditional plant knowledge represents thousands of years of empirical observation in the most rigorous sense — repeated application, observation of outcomes, and refinement over generations in the very environment in which the plants grow. Scientific validation using Western biomedical methods adds a particular type of evidence (laboratory and clinical trial data) that is useful for regulatory approval and global distribution, but it does not make the traditional knowledge more valid or legitimate — it simply translates it into a different knowledge system's terms.
Misconception: The Nagoya Protocol completely solves the problem of biopiracy.
The Nagoya Protocol is an important framework but has significant limitations. Not all countries have ratified it. Implementation requires domestic legislation that varies in strength and detail. It applies to resources accessed after it came into force in 2014 — not retrospectively to historical cases like the smoke bush patent. Oral traditional knowledge is still difficult to register as prior art in patent systems globally. And enforcement mechanisms are limited. The Protocol is a meaningful step but is not a comprehensive solution — ongoing advocacy for stronger domestic legislation and reformed patent systems is still required.
Biopiracy vs Ethical Use of Traditional Knowledge
Activities
The table below summarises three hypothetical research scenarios involving Australian bush medicine plants. Evaluate each scenario against the criteria of free prior informed consent (FPIC) and benefit sharing.
| Scenario | What happened | FPIC obtained? | Benefit sharing? |
|---|---|---|---|
| A | A university researcher learns from an Elder that a particular plant is used to treat infected wounds. The researcher collects samples, tests them, publishes results in a scientific journal, and acknowledges the community in the paper. No formal agreement was made. | Not formally | No financial benefit; acknowledgement only |
| B | A pharmaceutical company approaches a community with a formal research proposal. The community negotiates a benefit-sharing agreement (5% royalties on any commercial product) and gives written consent. The company develops a topical antibiotic. The community receives royalties. | Yes — formal written consent | Yes — negotiated royalties |
| C | A government agency collects plant samples under a general biodiversity collection permit. No community is consulted. Compounds are found to have antiviral activity. A patent is filed. The community is not notified. | No | No |
Write your responses here or in your book.
Choose one Australian bush medicine plant from those covered in this lesson (or one you research independently). In your book, produce an annotated entry that includes:
Type your notes or evaluative statement here after completing your annotated entry in your book.
You were asked who should benefit from a drug developed from traditional plant knowledge — the company, the community, or both. The law and ethics have been slowly converging on an answer: both, proportionally.
The company that isolates compounds, runs clinical trials, and navigates regulatory approval contributes genuinely to the drug's development — that investment deserves protection and return. But the traditional knowledge that directed researchers to the plant in the first place is also a contribution — one that may have taken thousands of years to develop and that the community owns collectively. Ignoring that contribution is not a neutral act; it is a choice to recognise one form of knowledge and dismiss another.
The Nagoya Protocol's answer is: negotiate before you start, share benefits equitably, and make the process transparent. This is not radical — it is the same logic that applies to any joint venture where multiple parties contribute to a commercial outcome. The radical idea, historically, was that traditional knowledge was free for the taking.
5 random questions from a replayable lesson bank — feedback shown immediately
1. Explain what biopiracy is, using the smoke bush case as a specific example. In your answer, identify what was taken, by whom, from which community, and why the community had no legal recourse under the existing patent system at the time. (3 marks)
2. Describe the key requirements of the Nagoya Protocol. Explain two limitations that mean it does not fully protect against biopiracy in all circumstances. (3 marks)
3. Evaluate the ethical obligations of researchers and pharmaceutical companies when using traditional Indigenous knowledge in drug development. In your answer, refer to the concepts of free prior informed consent, benefit sharing, and the difference between bioprospecting and biopiracy. (4 marks)
Answers
SA1 marking guide: 1 mark: biopiracy correctly defined (without consent; no benefit sharing) | 1 mark: smoke bush specifics (NCI; Conospermum; anti-HIV compounds; Noongar community) | 1 mark: no legal recourse — oral knowledge not in patent databases; not recognised as prior art
SA1: Biopiracy refers to the appropriation of traditional biological knowledge or genetic resources by a company, research institution, or government agency without the free prior informed consent of the knowledge-holding community, and without sharing any commercial benefits that result. In the smoke bush case, the US National Cancer Institute (NCI) collected samples of Conospermum species from Western Australia as part of a broad bioprospecting program. Laboratory screening identified compounds — later named conospermines — with significant activity against HIV in cell culture. The NCI filed a patent on these compounds. The Noongar people of south-western Western Australia had traditional knowledge of the smoke bush plant's medicinal properties — it had been used for generations for respiratory conditions and as part of healing ceremonies. The community was not consulted, was not notified of the patent filing, and was offered no benefit-sharing arrangement. The community had no effective legal recourse under the existing patent system at the time for a fundamental reason: their knowledge was oral, not documented in any written or indexed form that a patent examiner would search. Patent law requires a patent to be novel — but novelty is assessed by searching existing written prior art databases. Traditional oral knowledge, however ancient and well-established within a community, is not discoverable by patent search tools unless it has been recorded in an indexed written source. The Noongar community's knowledge therefore did not legally exist as prior art, and the patent could be granted without any acknowledgment of the traditional knowledge that had, in effect, directed researchers to the plant in the first place.
SA2 marking guide: 1 mark: Nagoya Protocol requirements correctly stated (FPIC; mutually agreed terms; benefit sharing) | 1 mark: limitation 1 with explanation | 1 mark: limitation 2 with explanation
SA2: The Nagoya Protocol on Access and Benefit-Sharing, adopted in 2010 and entering into force in 2014, establishes three core requirements for access to genetic resources and traditional knowledge for commercial purposes. First, free prior informed consent (FPIC) must be obtained from the community or country from which the resources or knowledge are taken — before research or collection begins. The consent must be genuinely free (not coerced), prior (given before access), and informed (the community understands what they are consenting to). Second, mutually agreed terms must be negotiated — the conditions of access must be agreed between the researcher/company and the community before any use of the knowledge occurs. Third, equitable benefit sharing must be agreed — any commercial benefits arising from the use of the resources must be shared with the providers according to the agreed terms. Despite these requirements the Protocol has two significant limitations. First it is not retrospective — it applies only to resources accessed after it entered into force in 2014. Historical cases of biopiracy such as the smoke bush patent are not covered; communities affected by pre-2014 appropriations have no remedy under the Protocol. Second effective implementation requires domestic legislation in each signatory country — and the strength and detail of this legislation varies considerably. Australia ratified the Protocol in 2022 but domestic access and benefit-sharing legislation is still developing at federal and state levels. Without strong domestic law the Protocol's requirements may not be enforceable in practice even for post-2014 cases.
SA3 marking guide: 1 mark: FPIC obligation — must be obtained before research begins; genuine and informed | 1 mark: benefit sharing — proportional to contribution of traditional knowledge | 1 mark: bioprospecting vs biopiracy distinction — process determines which applies | 1 mark: overall evaluation with reference to commercial value of traditional knowledge creating proportional obligation
SA3: Researchers and pharmaceutical companies working with traditional Indigenous knowledge have both ethical and, increasingly, legal obligations that extend well beyond what standard research ethics frameworks typically require. The first obligation is free prior informed consent. FPIC must be obtained before any research begins — not as a formality, but as a genuine process of engagement in which the community understands what is proposed, what the potential commercial outcomes are, who will own any resulting intellectual property, and what benefits they might receive. FPIC obtained after research has established promising findings is not truly free or prior — the power dynamic has already shifted. The second obligation is equitable benefit sharing. Traditional knowledge dramatically reduces the cost and time of drug development by directing researchers to biologically active compounds that might otherwise require years of random screening to identify. The commercial value of this contribution is substantial. Benefit-sharing agreements should reflect this — whether through royalties on commercial products, co-ownership of intellectual property, research funding for community health priorities, or other mutually agreed arrangements. Acknowledgement in a paper, while appropriate, is not a substitute for financial benefit sharing. The distinction between bioprospecting and biopiracy lies entirely in the process of engagement. The same plant compound can be the subject of ethical bioprospecting (with FPIC and a benefit-sharing agreement) or biopiracy (without these). Researchers cannot claim they were engaged in legitimate bioprospecting simply because they did not intend to harm the community — the standard is procedural, not intentional. Overall, the ethical obligations of researchers and companies in this area are proportional to the contribution that traditional knowledge makes to their research. Where traditional knowledge provides the essential lead that makes a commercial product possible — as in the smoke bush case — the obligation to obtain consent and share benefits is correspondingly strong. The development of the Nagoya Protocol and increasing domestic legislation in countries including Australia reflects a growing international consensus that traditional knowledge must be treated as an asset with a legitimate owner, not as a free resource available to whoever can exploit it first.